10-Year Free Cash Flow Projections(showing years 1, 3, 5, 7, 10)
| Year | Year 1 | Year 3 | Year 5 | Year 7 | Year 10 |
|---|
| Revenue | $408.6B | $478.4B | $550.7B | $619.5B | $694.2B |
| EBIT | $2.6B | $3.0B | $3.4B | $47.1B | $94.8B |
| Tax | $515M | $603M | $694M | $9.5B | $19.1B |
| NOPAT | $2.0B | $2.4B | $2.8B | $37.6B | $75.7B |
| + Depreciation | $802M | $940M | $1.1B | $1.2B | $1.4B |
| - Capex | $747M | $874M | $1.0B | $1.1B | $1.3B |
| - Δ NWC | $5.0B | $3.6B | $3.8B | $3.3B | $2.0B |
| Free Cash Flow | -$2.9B | -$1.2B | -$954M | $34.4B | $73.8B |
| Discount Factor | 0.944 | 0.842 | 0.751 | 0.670 | 0.564 |
| Present Value | -$2.7B | -$981M | -$717M | $23.0B | $41.6B |
FCF Formula: Free Cash Flow = NOPAT + Depreciation - Capex - Change in Net Working Capital
Sensitivity AnalysisPrice per Share
| WACC ↓ / Growth → | 2.00% | 2.50% | 3.00% | 3.50% | 4.00% |
|---|
| 3.89% | $17,361.76 | $16,601.95 | $15,878.86 | $15,190.52 | $14,535.13 |
| 4.89% | $13,122.60 | $14,482.18 | $15,878.86 | $15,190.52 | $14,535.13 |
| 5.89% | $10,467.97 | $11,122.28 | $12,002.72 | $13,251.02 | $14,535.13 |
| 6.89% | $8,743.63 | $9,113.12 | $9,577.51 | $10,178.74 | $10,987.77 |
| 7.89% | $7,496.71 | $7,726.53 | $8,003.31 | $8,343.10 | $8,770.15 |
How to read: This table shows how the valuation changes with different WACC (discount rate) and terminal growth rate assumptions. Green = undervalued, Red = overvalued.
Key Assumptions & Drivers✓ Using Analyst Consensus Estimates• Healthcare Sector
Growth Assumptions (Select Years)
Year 1 Revenue Growth13.80%
Year 3 Revenue Growth8.19%
Year 5 Revenue Growth7.37%
Year 7 Revenue Growth5.62%
Year 10 Revenue Growth3.00%
Terminal Growth Rate3.00%
Margin & Efficiency
Current EBIT Margin0.63%
Terminal EBIT Margin20.00%
Tax Rate20.14%
Historical Capex / Rev0.18%
NWC / Revenue10.00%
Key Drivers: Revenue growth, operating margin expansion, capex efficiency, and working capital management are the primary drivers of cash flow generation. Terminal value assumptions significantly impact final valuation.
Institutional-Grade Methodology
Actual Company Data: Revenue, EBIT, Capex, NWC, Tax Rate, Interest Expense, Beta
Market Assumptions: Risk-free: 4.5% (10Y), MRP: 4.5% (Damodaran 2026), Exit: 24x EV/EBITDA (Healthcare sector)
This DCF model is for informational purposes only. Projections are based on assumptions that may not materialize. Past performance does not guarantee future results. Consult a financial advisor before making investment decisions.